Payment overview · 2025
General Payments
$1,144.18
39 reported records · 11 companies
Healthcare provider profile · identity verified
Mihaela Iovanel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CUMBERLAND, RI · NPI 1710094321
Verified facts
What the public records show
CMS Open Payments records show Mihaela Iovanel, MD received $1,144.18 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Panzyga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $367.62 | 32.1% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $193.99 | 16.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $191.80 | 16.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $120.13 | 10.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $105.23 | 9.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.70 | 4.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.49 | 3.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.50 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.37 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.77 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.58 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,144.18 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $266.34 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $193.99 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $191.04 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $172.76 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $131.92 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.13 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $120.13 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $77.40 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.05 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
125 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 184 |
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 87 |
| Omeprazole | Omeprazole | 325 | 84 |
| Valsartan | Valsartan | 242 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 66 |
| Alprazolam | Alprazolam | 232 | 43 |
| Gabapentin | Gabapentin | 230 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 213 | 54 |
| Lorazepam | Lorazepam | 191 | 41 |
| Simvastatin | Simvastatin | 179 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 44 |
| Lisinopril | Lisinopril | 157 | 40 |
| Losartan Potassium | Losartan Potassium | 156 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 40 |
| Atenolol | Atenolol | 154 | 41 |
| Tramadol Hcl | Tramadol Hcl | 153 | 30 |
| Metformin Hcl | Metformin Hcl | 150 | 43 |
| Eliquis | Apixaban | 131 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 19 |
| Meloxicam | Meloxicam | 112 | 32 |
| Furosemide | Furosemide | 109 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 30 |
| Sertraline Hcl | Sertraline Hcl | 106 | 31 |
| Trazodone Hcl | Trazodone Hcl | 105 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 17 |
| Ozempic | Semaglutide | 98 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 97 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 13 |
| Metformin Hcl Er | Metformin Hcl | 75 | 20 |
| Lovastatin | Lovastatin | 73 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 14 |
| Donepezil Hcl | Donepezil Hcl | 69 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 15 |
| Alendronate Sodium | Alendronate Sodium | 61 | 14 |
| Ibuprofen | Ibuprofen | 59 | 15 |
| Bupropion Xl | Bupropion Hcl | 54 | 14 |
| Telmisartan | Telmisartan | 53 | suppressed |
| Jardiance | Empagliflozin | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 48 | 12 |
| Famotidine | Famotidine | 48 | suppressed |
| Trulicity | Dulaglutide | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | 12 |
| Glimepiride | Glimepiride | 43 | 16 |
| Naproxen | Naproxen | 43 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 16 |
| Diazepam | Diazepam | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Temazepam | Temazepam | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Baclofen | Baclofen | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,144.18 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error